CANDI LONG: Open Payments
NPI 1154920593 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$519 in 18 payments from 8 companies in 2025. Trend: 2023 $202 · 2024 $18 · 2025 $519
Food & beverage: $519
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 6 | $166 |
| AstraZeneca Pharmaceuticals LP | 1 | $122 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $110 |
| Boston Scientific Corporation | 2 | $38 |
| Alkermes, Inc. | 1 | $29 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Dexcom, Inc. | 1 | $18 |
| Janssen Pharmaceuticals, Inc | 1 | $15 |
Products named: FASENRA, REXULTI, CAPLYTA, ABILIFY ASIMTUFII, General - Pain Management, ARISTADA, AUSTEDO XR, Dexcom G6 Transmitter.
Industry payments across NV — which companies pay providers there.
